272 related articles for article (PubMed ID: 31084595)
1. Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Ekinci E; Rohondia S; Khan R; Dou QP
Recent Pat Anticancer Drug Discov; 2019; 14(2):113-132. PubMed ID: 31084595
[TBL] [Abstract][Full Text] [Related]
2. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Kona FR; Buac D; M Burger A
Curr Cancer Drug Targets; 2011 Mar; 11(3):338-46. PubMed ID: 21247383
[TBL] [Abstract][Full Text] [Related]
3. Cancer Pro-oxidant Therapy Through Copper Redox Cycling:
Rieber M
Curr Pharm Des; 2020; 26(35):4461-4466. PubMed ID: 32600223
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
5. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Triscott J; Rose Pambid M; Dunn SE
Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
[TBL] [Abstract][Full Text] [Related]
6. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
Skrott Z; Mistrik M; Andersen KK; Friis S; Majera D; Gursky J; Ozdian T; Bartkova J; Turi Z; Moudry P; Kraus M; Michalova M; Vaclavkova J; Dzubak P; Vrobel I; Pouckova P; Sedlacek J; Miklovicova A; Kutt A; Li J; Mattova J; Driessen C; Dou QP; Olsen J; Hajduch M; Cvek B; Deshaies RJ; Bartek J
Nature; 2017 Dec; 552(7684):194-199. PubMed ID: 29211715
[TBL] [Abstract][Full Text] [Related]
7. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
8. An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Yang Q; Yao Y; Li K; Jiao L; Zhu J; Ni C; Li M; Dou QP; Yang H
Curr Pharm Des; 2019; 25(30):3248-3256. PubMed ID: 31419930
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram: a novel repurposed drug for cancer therapy.
Lu C; Li X; Ren Y; Zhang X
Cancer Chemother Pharmacol; 2021 Feb; 87(2):159-172. PubMed ID: 33426580
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Calderon-Aparicio A; Strasberg-Rieber M; Rieber M
Oncotarget; 2015 Oct; 6(30):29771-81. PubMed ID: 26356671
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms.
Sun F; Wang H; Nie J; Hong B
Anticancer Agents Med Chem; 2022; 22(17):2920-2926. PubMed ID: 35430981
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.
Viola-Rhenals M; Patel KR; Jaimes-Santamaria L; Wu G; Liu J; Dou QP
Curr Med Chem; 2018 Feb; 25(4):506-524. PubMed ID: 29065820
[TBL] [Abstract][Full Text] [Related]
13. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors.
Banerjee P; Geng T; Mahanty A; Li T; Zong L; Wang B
Int J Pharm; 2019 Feb; 557():374-389. PubMed ID: 30610896
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Brar SS; Grigg C; Wilson KS; Holder WD; Dreau D; Austin C; Foster M; Ghio AJ; Whorton AR; Stowell GW; Whittall LB; Whittle RR; White DP; Kennedy TP
Mol Cancer Ther; 2004 Sep; 3(9):1049-60. PubMed ID: 15367699
[TBL] [Abstract][Full Text] [Related]
16. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
17. Plasma extracellular superoxide dismutase and erythrocyte Cu,Zn-containing superoxide dismutase in alcoholics treated with disulfiram.
Ohman M; Marklund SL
Clin Sci (Lond); 1986 Apr; 70(4):365-9. PubMed ID: 3698512
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
19. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D; Skrott Z; Bouchal J; Bartkova J; Simkova D; Gachechiladze M; Steigerova J; Kurfurstova D; Gursky J; Korinkova G; Cwiertka K; Hodny Z; Mistrik M; Bartek J
Prostate; 2019 Mar; 79(4):352-362. PubMed ID: 30499118
[TBL] [Abstract][Full Text] [Related]
20. Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Hwang S; Shin DM; Hong JH
Molecules; 2019 Sep; 24(18):. PubMed ID: 31546841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
